A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Phase of Trial: Phase I/II
Latest Information Update: 01 Sep 2018
At a glance
- Drugs Cabazitaxel (Primary)
- Indications Glioma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sanofi
- 31 Aug 2018 Biomarkers information updated
- 01 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Nov 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.